Articles tagged with Drug Therapy
Researchers at Keck School of Medicine of USC are testing the efficacy of 3K3A-APC as a cerebroprotectant to reduce brain bleeds in acute ischemic stroke patients. The experimental drug has shown promising results in Phase 2 clinical trials, reducing incidence of brain hemorrhage by nearly 20%.
Researchers at the University of Virginia Health System have made important discoveries on the crucial role of malnutrition in global tuberculosis, highlighting how gut infections impair treatment outcomes. A new funding partnership will train Tanzanian postdoctoral researchers to work specifically on this intersection.
Daily gabapentin treatment restored fine motor functions in mice's upper extremities and continued to show functional improvements even after treatment was stopped. The drug blocks the activity of a protein that hinders re-growth of axons, enabling post-stroke central nervous system repair to progress in a coordinated way.
Researchers found that polypharmacy and sedative drugs are associated with an increased risk of long-term care needs certification among older adults. The study highlights the need for public health initiatives to reduce high-risk prescribing practices, which may lead to a decrease in disability risk.
Researchers at Penn Medicine have developed an imaging agent that detects cancer cells in real-time during biopsies, offering promise for earlier and more accurate diagnoses. The technology, known as NIR-nCLE, uses a combination of near-infrared tracers and confocal laser endomicroscopy to identify microscopic cancer cells.
Researchers at MedUni Vienna identified five distinct subtypes of small cell lung cancer, each responding differently to therapies. High ASCL1 expression is linked to poor survival, while high POU2F3 expression correlates with better outcomes and sensitivity to standard chemotherapeutics.
A team of scientists led by Professor Barbara Pierscionek has made significant progress in developing an anti-cataract drug. Lab trials showed improvement in refractive index profiles and lens opacity in 61% and 46% of cases, respectively.
A large study has found six predictors that can help determine the optimal lithium dose for patients with bipolar disorder. The predictors include age, sex, kidney function, and medication use. The researchers hope to develop a digital app to aid psychiatrists in finding the right dose.
A recent study analyzed a large database of bladder cancer patients and found that fewer than half had been tested for the relevant gene mutation or received erdafitinib treatment, despite its proven efficacy. The research highlights significant barriers to treatment, including obstacles in testing and education for healthcare providers.
Researchers have developed a process to convert non-neuronal cells into functioning neurons that can take up residence in the brain and restore capacities undermined by Parkinson's destruction of dopaminergic cells. In a proof-of-concept study, one group of experimentally engineered cells performs optimally in terms of survival, growth...
Researchers at H. Lee Moffitt Cancer Center & Research Institute have identified key factors impacting the effectiveness of adaptive therapy in cancer treatment. The study found that spatial organization and competition between drug-resistant cells play a crucial role in determining the success of adaptive therapy.
A new drug called abemaciclib has been shown to halt the growth of recurring brain tumors in patients with aggressive meningiomas. The treatment targets a common molecular pathway that enables cells to divide rapidly and come back after surgery, allowing researchers to predict recurrence more accurately.
Researchers have discovered a way to suppress a specific protein that promotes resistance to drugs commonly used to treat AML patients. This breakthrough has the potential to revolutionize treatment and prolong survival for those affected by the disease.
A team of international researchers created digital models of disease interactions to identify key proteins and signaling cascades in seasonal allergies. They found that inhibiting PDGF-BB protein was more effective than existing treatments, suggesting a potential breakthrough in personalized medicine.
Researchers developed a droplet-based microfluidic technology to produce micro-organospheres from cancer patient biopsies within an hour. These miniature tumors retain the original microenvironment and can be used for testing many drug conditions, showing almost perfect correlation with actual clinical treatment outcomes.
Researchers at the University of Missouri are applying AI to analyze protein dynamics, identifying potential target sites for new drug therapies. The approach can simulate protein changes related to conditions like cancer, enhancing the chances of successful therapies.
Researchers created patient-derived models of brain metastases that recapitulate human disseminated disease, reflecting clinical manifestations and biological characteristics. These models can be used to test therapeutic value of different treatments and explore new approaches tailored to each patient.
The joint guide provides a framework for establishing theranostic centers globally, focusing on safety protocols and operational procedures. It highlights best practices for radiation protection, storage, administration, and other topics to improve patient care.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers at Tokyo University of Science identify brain regions and signaling pathways involved in fear extinction via delta receptor activation. The study suggests a potential therapeutic agent for post-traumatic stress disorders by suppressing fearful memories.
A new study estimates the national economic burden of PTSD at $232.2 billion for 2018, with civilians accounting for 82% of the total costs. The study calls for increased awareness, effective therapies, and expanded evidence-based strategies to reduce the clinical and economic burden of PTSD.
A NIH-funded study found that patients with retinal vein occlusion experience significant visual acuity gains, but require long-term monitoring and treatment. After five years, many participants retained an average of three lines of improvement in their visual acuity.
Researchers are developing radioconjugate drugs that combine radiation with a tumor-targeting agent to selectively kill cancer cells. Two approved drugs, Lutathera and Pluvicto, demonstrate the potential of this therapy, which could change the future of cancer treatment.
A study has identified a new protein, Creb-binding protein (CBP), as a prognostic marker for above-average patient survival in HPV-positive head and neck carcinoma. CBP inhibitors are being developed as targeted therapies that can improve quality of life by reducing side effects associated with conventional chemotherapy or radiotherapy.
A new study found that Black kidney transplant recipients exhibit a faster clearance rate of tacrolimus, an immunosuppressive drug. The study suggests that considering both sex and race when dosing tacrolimus may reduce adverse effects and enhance transplant outcomes.
Researchers have found that treating prostate cancer cells with novel CDK8 and CDK19 inhibitors reduces their potential to migrate into surrounding structures. This suggests a promising approach to overcome resistance against anti-androgenic therapy, offering new therapeutic options for patients with advanced disease.
Researchers at Rutgers University propose a new approach to COVID-19 vaccine testing by combining conventional and challenge trials. This parallel approach, called Combining Conventional and Challenge trials (CCC), aims to facilitate faster and more accurate vaccine assessment and more effective pandemic response.
Researchers evaluated monoclonal antibody administration methods and their impact on COVID-19 hospitalization and death rates. The study found no significant difference in effectiveness between injection and intravenous administration, suggesting that injection could expand outpatient treatment capacity.
The TTUHSC's C. Patrick Reynolds has received a $1.34 million CPRIT grant to investigate updating the clinical risk stratification scale for neuroblastoma and rhabdomyosarcoma, two childhood cancers in need of improved therapies.
A randomized clinical trial found that participants treated at non-stigmatizing 'accessible care' centers were nearly three times more likely to be cured of hepatitis C than those referred out to local clinicians. The study suggests that expanding and supporting accessible care models could help eliminate the disease.
Recent studies published in the Journal of Pharmaceutical Analysis have found applications of nanotechnology in medicine, drug research, and environmental protection. Researchers developed nanodots made of carbon using natural polysaccharides from mushrooms to detect chromium, and created nanozymes that could be used to detect drug con...
Researchers have discovered a potential new treatment for glioblastoma, which targets 'kinase' proteins to limit tumour growth and improve existing chemotherapeutic drugs. This breakthrough therapy may provide hope for patients with aggressive brain tumours, offering a more effective and sustainable approach to treatment.
A large US study confirms a strong link between ED medications and vision problems, including an 85% increased risk of developing serious eye conditions. Regular use of Viagra, Cialis, Levitra, or Stendra may lead to side effects such as age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
Finnish researchers created a comprehensive map of molecular interactions between 58 human receptor tyrosine kinases (RTKs), revealing key insights into their functions and roles in disease. The study's findings can aid understanding of diseases linked to abnormal RTK activity, particularly cancer.
Scientists create nanoparticles coated in mannose to block production of scar-promoting protein in lung cells. The treatment holds promise for preventing severe lung scarring disease.
A recent study published in Molecular Therapy Nucleic Acids found that the molecule urocortin-2 may regulate recovery processes after a heart attack by modulating miR-29a. Treatment with urocortin-2 could favor patient recovery by regulating apoptosis and fibrosis.
A new study found that customized digital alerts via an electronic health record system significantly increased the number of guideline-directed medications prescribed for heart failure patients. The alerts improved medication use by over a quarter of patients, translating to one medication addition per every 14 alerts received.
Researchers at the University of Eastern Finland have developed a novel nuclear microRNA, miR-466c, that regulates vascular endothelial growth factor A (VEGFA) expression in response to hypoxia. The drug has commercial relevance for treating ischemic cardiovascular disease by increasing VEGFA levels.
A Johns Hopkins-led study published in New England Journal of Medicine found that convalescent plasma from recovered COVID-19 patients can effectively treat outpatients, with a 54% reduced need for hospitalization. The therapy's effectiveness increases with earlier administration within five days after diagnosis.
Levi A. Garraway is being honored for his groundbreaking contributions to cancer research, including the identification of melanoma genes and development of precision oncology approaches. He has also championed parallel sequencing as a definitive approach to tumor genomic profiling, revolutionizing cancer treatment strategies.
Researchers at Penn Medicine have developed a new approach to alter immune cells for CAR T cell therapy in just 24 hours, cutting manufacturing time from nine to 14 days. This could make the therapy more cost-effective and accessible to more patients.
Researchers developed a method to identify aggressive early-stage lung cancers and target drugs to tumors likely to respond. They used genomics network models and identified signature genes associated with tumor invasiveness.
Researchers developed a novel drug to reduce airway mucus that exacerbates common lung diseases. The treatment works by blocking the secretion of mucins, which can block airways and cause life-threatening symptoms.
The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.
Researchers at Indiana University School of Medicine found that niacin modulates microglia response to amyloid plaques in an Alzheimer's disease animal model. The study identifies a potential novel therapeutic target for the disease, which can be modulated by FDA-approved drugs.
Researchers report promising results from a phase 3 clinical trial of MDMA-assisted therapy for post-traumatic stress disorder (PTSD), with two-thirds of participants no longer meeting the diagnostic criteria. The therapy showed better effect sizes than selective serotonin reuptake inhibitors (SSRIs) and was equally effective in treatm...
A new study led by Kelly Monaghan at West Virginia University suggests that interrupting the immune response may improve multiple sclerosis outcomes. The researchers found that targeting a specific protein called CCL17 can prevent the disease from attacking the central nervous system, leading to milder symptoms and delayed paralysis.
Researchers have found that immune checkpoint inhibitors like pembrolizumab can slow disease progression in patients with high-grade meningiomas. The study showed that nearly half of all patients were alive and without evidence of disease progression for at least 6 months after treatment.
Researchers at UC Berkeley discover that Antabuse helps improve sight in mice with retinal degeneration by reducing hyperactive retinal cells. The treatment may one day lead to better therapies for humans with inherited diseases like retinitis pigmentosa.
Researchers from UCLA Health and Harvard Medical School propose a new approach to studying and applying psychedelic compounds to foster intentional changes in habits and behaviors, potentially leading to improved health and resilience.
Researchers at Weill Cornell Medicine found that certain Candida albicans yeast strains produce a potent toxin called candidalysin, which damages immune cells and triggers pro-inflammatory responses. The study suggests a possible way to personalize treatments for IBD patients by targeting these high-damaging strains.
Researchers have developed a monoclonal antibody called PRN100, which showed safe and encouraging results in treating Creutzfeldt-Jakob disease (CJD) in six patients. While the findings are preliminary and require further studies, they offer new prospects for this rare and fatal disease.
A study in rural Ethiopia found that community-based rehabilitation, supported by local health centers and medication, reduced symptoms and improved functioning for individuals with schizophrenia. Community-based rehabilitation workers also helped participants access healthcare services and support their families.
A new study reveals that intra-tumoral injections of a plant virus-based immunotherapy could lead to groundbreaking therapy for both canine and human inflammatory breast cancer patients. The treatment generated potent local and systemic anti-tumor immune responses, improving quality of life and survival in treated dogs.
A study at Duke-NUS Medical School found that inhibiting IL-11 can reduce kidney damage, inflammation, and scarring in Alport syndrome mice. Combining this therapy with ACEi treatment increased lifespan by over 400%.
Researchers at the University of South Australia have developed a new way to deliver chemotherapy drugs, using liposomal formulations that target tumors more effectively. This breakthrough could improve treatment outcomes for thousands of cancer patients, reducing side effects and improving quality of life.
Researchers found that four-month treatment is as effective as six months in non-severe TB cases, allowing for savings on screening and training healthcare workers. The study's results led to a change in the World Health Organisation's global guidelines, recommending a shorter treatment course for children with non-severe TB.
The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors approved funding for 12 new comparative clinical effectiveness research studies focusing on maternal health, autism, and urinary incontinence. These studies will improve healthcare delivery and health outcomes in real-world settings.
Scientists at the Max Planck Institute of Biochemistry have discovered a new subtype of acute myeloid leukemia (AML) characterized by high amounts of mitochondrial proteins and altered mitochondrial metabolism. This subtype, called Mito-AML, shows clinical resistance to chemotherapy and can be effectively combated with inhibitors again...
Researchers found that verapamil treatment delayed disease progression, lowered insulin requirements, and preserved some beta cell function in patients with Type 1 diabetes. The study used proteomics analysis and RNA sequencing to examine changes in circulating proteins in response to verapamil treatment.